Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in Citi’s 2025 Global Healthcare ...

The stock of niche financial software company Vertex ( VERX 4.13%) didn't get a very good start to the trading week at all. Its value fell by nearly 10% that day, due largely to a quarterly earnings ...

Vertex Pharmaceuticals (NASDAQ: VRTX) has not performed well for most of the year, and the company's latest quarterly update ...

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

The Vertex Configuration Agent for Microsoft Dynamics 365 helps businesses stay ahead of change by keeping tax configurations continuously aligned as their operations evolve. Powered by Vertex AI and ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best gene-editing stocks to buy according to hedge funds. On ...

Vertex Pharmaceuticals chief Reshma Kewalramani said AI could reduce the time spent on drug-approval paperwork from months to ...

Vertex (NASDAQ: VERX) delivered a split result this morning that left investors parsing mixed signals. The tax technology ...

With immunology and inflammation blockbusters like AbbVie’s Skyrizi and Rinvoq reeling in nearly $7 billion combined in the ...

KING OF PRUSSIA, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results ...

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 3.33% to $421.03 Wednesday, on what proved to be an all-around favorable ...

In the U.S., revenue climbed 15%, to $1.98 billion, helped by strong demand and higher pricing for its cystic-fibrosis drugs, the company said. Its Casgevy and Journavx drugs, which treat severe ...